Oculis (NASDAQ:OCS) Hits New 52-Week High – What’s Next?

Oculis Holding AG (NASDAQ:OCS) shares hit a new 52-week high during mid-day trading on Monday . The company traded as high as $18.00 and last traded at $17.83, with a volume of 13043 shares changing hands. The stock had previously closed at $17.88.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Oculis in a research report on Wednesday, October 23rd. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Oculis has a consensus rating of “Buy” and a consensus price target of $29.20.

Oculis Trading Down 0.3 %

The stock has a market capitalization of $721.71 million, a P/E ratio of -9.31 and a beta of -0.18. The stock’s fifty day moving average price is $13.50 and its two-hundred day moving average price is $12.43. The company has a current ratio of 5.27, a quick ratio of 5.27 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS) last posted its quarterly earnings results on Tuesday, August 27th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.13). Oculis had a negative return on equity of 61.33% and a negative net margin of 7,679.05%. The company had revenue of $0.27 million for the quarter, compared to the consensus estimate of $0.28 million. Equities research analysts forecast that Oculis Holding AG will post -2.19 EPS for the current year.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.